These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16940806)

  • 1. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
    Orlando L; Cardillo A; Rocca A; Balduzzi A; Ghisini R; Peruzzotti G; Goldhirsch A; D'Alessandro C; Cinieri S; Preda L; Colleoni M
    Anticancer Drugs; 2006 Sep; 17(8):961-7. PubMed ID: 16940806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
    Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
    J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
    BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.
    Gebbia V; Boussen H; Valerio MR
    Anticancer Res; 2012 Feb; 32(2):529-36. PubMed ID: 22287742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A study of complete responders in cases of metastatic breast cancer treated with combination chemotherapy].
    Shinagawa K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Fukutani H; Tabata M; Hirano A; Mizunuma N
    Gan No Rinsho; 1989 Apr; 35(5):581-6. PubMed ID: 2541272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
    Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
    Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.
    Young SD; Whissell M; Noble JC; Cano PO; Lopez PG; Germond CJ
    Clin Cancer Res; 2006 May; 12(10):3092-8. PubMed ID: 16707607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.
    Aurilio G; Munzone E; Botteri E; Sciandivasci A; Adamoli L; Minchella I; Esposito A; Cullurà D; Curigliano G; Colleoni M; Goldhirsch A; Nolè F
    Breast J; 2012 Sep; 18(5):470-4. PubMed ID: 22827581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
    Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance treatment in metastatic breast cancer.
    Sánchez-Muñoz A; Pérez-Ruiz E; Ribelles N; Márquez A; Alba E
    Expert Rev Anticancer Ther; 2008 Dec; 8(12):1907-12. PubMed ID: 19046111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
    J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.
    Fousseyni T; Diawara M; Pasquier E; André N
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):31-4. PubMed ID: 21164360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy.
    Miscoria M; Tonetto F; Deroma L; Machin P; Di Loreto C; Driol P; Minisini AM; Russo S; Andreetta C; Mansutti M; Damante G; Fasola G; Puglisi F
    Anticancer Drugs; 2012 Mar; 23(3):326-34. PubMed ID: 22129512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
    Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
    Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
    Nicolini A; Mancini P; Ferrari P; Anselmi L; Tartarelli G; Bonazzi V; Carpi A; Giardino R
    Biomed Pharmacother; 2004 Oct; 58(8):447-50. PubMed ID: 15464874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185).
    Pandya KJ; Hu P; Osborne CK; Falkson G; Tormey DC;
    Am J Clin Oncol; 2007 Apr; 30(2):113-25. PubMed ID: 17414459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit.
    Kurian S; Qazilbash M; Fay J; Wolff S; Herzig R; Hobbs G; Bunner P; Weisenborn R; Aya-Ay M; Lynch J; Ericson S
    Breast J; 2006; 12(6):531-5. PubMed ID: 17238982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic results and toxic side effects of the cytostasan, adriamycin and vincristine combination as second line therapy in metastatic breast cancer].
    Brockmann B; Geschke E; Schmidt UM; Ebeling K
    Geburtshilfe Frauenheilkd; 1991 May; 51(5):383-6. PubMed ID: 1869008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.